CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia

This is a Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and Adolescents (4-18 years) With Hyperchylomicronemia

NCT Number	NCT07371767
Lead Sponsor	Shanghai Jiao Tong University School of Medicine Collaborators: CorrectSequence Therapeutics Co., Ltd
Conditions	Hyperchylomicronemia
Enrollment	15 participants
Start Date	2026-01-26
Primary Completion	2027-10-31 (estimated)
Study Completion	2041-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-28